celecoxib and mk 0663

celecoxib has been researched along with mk 0663 in 73 studies

Research

Studies (73)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	35 (47.95)	29.6817
2010's	28 (38.36)	24.3611
2020's	10 (13.70)	2.80

Authors

Authors	Studies
Byun, Y; Choi, JK; Choi, YH; Chung, S; Jeong, YS; Kim, JK; Kim, JY; Koh, HJ; Lee, KW; Lim, KM; Moh, JH; Noh, MS; Oh, YI; Park, YH; Shin, SS	1
Beswick, P; Bingham, S; Bountra, C; Brown, T; Browning, K; Campbell, I; Chessell, I; Clayton, N; Collins, S; Corfield, J; Guntrip, S; Haslam, C; Lambeth, P; Lucas, F; Mathews, N; Murkit, G; Naylor, A; Pegg, N; Pickup, E; Player, H; Price, H; Stevens, A; Stratton, S; Wiseman, J	1
Augustyniak, ME; Earl, RA; Garvey, DS; Janero, DR; Khanapure, SP; Letts, LG; Martino, AM; Murty, MG; Schwalb, DJ; Shumway, MJ; Trocha, AM; Young, DV; Zemtseva, IS	1
Barreiro, EJ; Fraga, CA; Lima, LM; Sant'Anna, CM; Sperandio da Silva, GM	1
Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Ramajayam, R	1
Bachman, KE; Bonnette, WG; Chen, H; Connolly, PJ; Dallas, S; Diloreto, KA; Dong, Y; Edwards, JP; Evans, DC; Ghosh, A; King, P; Li, X; Liao, D; Pande, V; Patel, S; Pietrak, B; Sensenhauser, C; Shi, Y; Suarez, J; Szewczuk, L; Tian, G; Wang, J; Wilde, T; Zhang, Z	1
Ouellet, M; Percival, MD; Riendeau, D	1
Hardy, KJ; McMurray, RW	1
Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT	1
Chan, VS	1
Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B	1
Hochberg, MC	1
Meena, S; Nageswara Rao, R; Raghuram Rao, A	1
Mullangi, R; Pavan Kumar, VV; Ramani, AV; Srinivas, NR; Vinu, MC	1
Krüger, K	1
Caballero-Fonseca, F; Capriles-Hulett, A; Sánchez-Borges, M	1
Andersohn, F; Garbe, E; Schade, R; Suissa, S	1
Boshier, A; Friedmann, P; Layton, D; Marshall, V; Shakir, SA	1
Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM	1
Broich, K; Heim, HK	1
Hilário, MO; Len, CA; Terreri, MT	1
Tabrizchi, R	1
Ashcroft, DM; Chen, LC	1
Bjarnason, NH; Gøtzsche, PC	1
Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C	1
Klotz, U; Shi, S	1
Cavanaugh, PF; Chappell, DL; Dallob, AL; Flynn, ME; Hilliard, DA; Larson, PJ; Laterza, OF; Miller, J; Royalty, J; Schwartz, JI; Snyder, KM; Wagner, JA	1
Bingham, CO; Bird, SR; Smugar, SS; Tershakovec, AM; Xu, X	1
Lesaffre, E	2
Caspers, P; Gijsen, R; Jochemsen, H; van Dijk, L	1
Diza, E; Gika, HG; Michopoulos, F; Nikolaidis, P; Settas, L; Smith, C; Theodoridis, G; Theodoridou, A; Wilson, ID	1
Sharma, P; Suresh, S	1
Bingham, CO; Smugar, SS; Tershakovec, AM; Wang, H	1
Mahadik, KR; Paradkar, AR; Shimpi, SL	1
Avila, R; Cimbollek, S; Quiralte, J	1
Choy, EH; Gaugris, S; Jansen, JP; Nash, JT; Ostor, A; Stam, W	1
Elliott, WJ	1
Chang, FY; Chen, TS; Hsiang, KW; Lee, KC; Lee, SD; Lin, HC; Lin, HY; Lu, CL; Luo, JC	1
Honjo, H; Iwamoto, K; Uwai, Y	1
Boonriong, T; Glabglay, P; Nimmaanrat, S; Tangtrakulwanich, B	1
Pilatti, GL; Santos, FA; Steffens, JP	1
Bingham, CO; Gammaitoni, A; Peloso, PM; Smugar, SS; Wang, H	1
Janovsky, M; Krsiak, M	1
Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P	1
Dávila, I; González, A; Laffond, E; Moreno, E; Muñoz-Bellido, F; Ponce, V	1
Caro Gutiérrez, D; Gómez de la Fuente, E; López Estebaranz, JL; Pampín Franco, A	1
Ariano, C; Baldi, C; Cantatrione, S; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Valente, L	1
Baek, HJ; Bin, SI; Cho, YJ; Cukrow, DM; Kang, SB; Kim, SS; Lee, SW; Mehta, A; Min, BW; Moon, KH; Moon, SH; Park, YW; Shim, SC; Skuban, A; Song, YW; Vandormael, K; Yan, L; Yoo, DH; Yoo, MC; Yoo, WH	1
Aujla, U; Bjarnason, I; Kvasnovsky, CL	1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y	1
Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F	1
Dulski, M; Grzybowska, K; Jurkiewicz, K; Knapik, J; Paluch, M; Rams-Baron, M; Ratuszna, A; Sawicki, W; Smolka, W; Wojnarowska, Z	1
Hansen, SH; Skonberg, C; Syed, M	1
Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG	1
Katchamart, W; Suwanawiboon, B; Tantayakom, P; Teerawattananon, C	1
Ghanghas, P; Jain, S; Rana, C; Sanyal, SN	2
Carracedo-Martínez, E; Figueiras, A; Pia-Morandeira, A	1
Davydkin, IL; Zolotovskaia, IA	1
Martín Arias, LH; Martín González, A; Sanz Fadrique, R; Vazquez, ES	1
Amaro, C; Ferreira, ML; Miroux-Catarino, A; Silva, L; Viana, I	1
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K	1
Ahn, K; Connolly, P; Suarez, J; Tian, G; Zhang, Z	1
Bahra, A; Farag, M	1
Ding, X; Li, X; Lu, N; Wang, Y; Wu, Z	1
Hjemdahl, P; Stiller, CO	1
Pedersen, L; Schmidt, M; Sørensen, HT	1
González-Fernández, T; López-Freire, S; Méndez-Brea, P; Romero-Sánchez, L	1
Cvijić, S; Dahan, A; Dukhno, O; Partook-Maccabi, M; Porat, D; Vainer, E	1
Chau, C; Cheung, G; Chu, EC; Huang, KH; Tam, D	1

Reviews

20 review(s) available for celecoxib and mk 0663

Article	Year
Medicinal chemistry of vicinal diaryl scaffold: A mini review. European journal of medicinal chemistry, 2019, Jan-15, Volume: 162 Topics: Carbonic Anhydrase IV; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Drug Discovery; Humans; Hydrocarbons, Aromatic; Structure-Activity Relationship	2019
Cox-2 inhibitors: today and tomorrow. The American journal of the medical sciences, 2002, Volume: 323, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones	2002
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. Drug safety, 2004, Volume: 27, Issue:7 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2004
First and second generations of COX-2 selective inhibitors. Mini reviews in medicinal chemistry, 2004, Volume: 4, Issue:6 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2004
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome	2005
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Industry; Etodolac; Etoricoxib; Lactones; Models, Chemical; Pyrazoles; Pyridines; Spectrophotometry; Sulfonamides; Sulfones; Ultraviolet Rays	2005
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs]. MMW Fortschritte der Medizin, 2005, Aug-04, Volume: 147, Issue:31-32 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Gout; Humans; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Rheumatic Diseases; Spondylitis, Ankylosing; Sulfonamides; Sulfones	2005
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors. Jornal de pediatria, 2006, Volume: 82, Issue:5 Suppl Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Fever; Humans; Hypersensitivity, Immediate; Inflammation; Leukotrienes; Meloxicam; Naproxen; Pain; Prostaglandins; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome	2006
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2007
Clinical use and pharmacological properties of selective COX-2 inhibitors. European journal of clinical pharmacology, 2008, Volume: 64, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2008
Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis and cartilage, 2008, Volume: 16, Issue:11 Topics: Aged; Analysis of Variance; Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Female; Health Status Indicators; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome	2008
Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology (Oxford, England), 2009, Volume: 48, Issue:9 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Prognosis; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Time Factors; Treatment Outcome	2009
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Current hypertension reports, 2010, Volume: 12, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones	2010
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva cardioangiologica, 2014, Volume: 62, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Naproxen; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2014
Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scandinavian journal of gastroenterology, 2015, Volume: 50, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Observational Studies as Topic; Pain; Pyrazoles; Pyridines; Recurrence; Sulfonamides; Sulfones	2015
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones	2014
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Zeitschrift fur Rheumatologie, 2016, Volume: 75, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome	2016
Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis. Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:4 Topics: Blood Loss, Surgical; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Isoxazoles; Postoperative Hemorrhage; Pyridines; Risk Factors; Sulfones	2017
Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. Journal of clinical pharmacology, 2019, Volume: 59, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Etoricoxib; Humans; Observational Studies as Topic; Risk Factors	2019
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. Journal of internal medicine, 2022, Volume: 292, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes	2022

Trials

8 trial(s) available for celecoxib and mk 0663

Article	Year
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:2 Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Urticaria	2005
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyrazoles; Pyridines; Severity of Illness Index; Sulfonamides; Sulfones; Thrombosis; Treatment Outcome	2007
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. Journal of clinical pharmacology, 2007, Volume: 47, Issue:12 Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Celecoxib; Constipation; Creatinine; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Etoricoxib; Female; Headache; Humans; Male; Middle Aged; Naproxen; Potassium; Prostaglandins; Pyrazoles; Pyridines; Sodium; Sulfonamides; Sulfones; Thromboxane B2	2007
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. Journal of clinical pharmacology, 2008, Volume: 48, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thromboxane B2	2008
Comparing etoricoxib and celecoxib for preemptive analgesia for acute postoperative pain in patients undergoing arthroscopic anterior cruciate ligament reconstruction: a randomized controlled trial. BMC musculoskeletal disorders, 2010, Oct-25, Volume: 11 Topics: Adolescent; Adult; Analgesia; Arthroscopy; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Pain, Postoperative; Preoperative Care; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Young Adult	2010
The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial. Journal of periodontology, 2011, Volume: 82, Issue:9 Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Celecoxib; Chronic Periodontitis; Cyclooxygenase 2 Inhibitors; Debridement; Dental Anxiety; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gingival Hemorrhage; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebos; Premedication; Prospective Studies; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Surgical Flaps; Treatment Outcome; Young Adult	2011
Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo. Pain medicine (Malden, Mass.), 2011, Volume: 12, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Treatment Outcome	2011
Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. Current medical research and opinion, 2014, Volume: 30, Issue:12 Topics: Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Republic of Korea; Sulfonamides; Sulfones; Treatment Outcome	2014

Other Studies

45 other study(ies) available for celecoxib and mk 0663

Article	Year
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. Journal of medicinal chemistry, 2004, Feb-12, Volume: 47, Issue:4 Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Furans; Humans; In Vitro Techniques; Isoenzymes; Macrophages, Peritoneal; Male; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship	2004
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2004, Nov-01, Volume: 14, Issue:21 Topics: Administration, Oral; Animals; Arthritis, Experimental; Biological Availability; Brain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Freund's Adjuvant; Humans; Infusions, Intravenous; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridazines; Rats; Structure-Activity Relationship	2004
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation. Journal of medicinal chemistry, 2005, Jun-02, Volume: 48, Issue:11 Topics: Administration, Oral; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Inflammation; Male; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones	2005
The molecular basis for coxib inhibition of p38alpha MAP kinase. Bioorganic & medicinal chemistry letters, 2005, Aug-01, Volume: 15, Issue:15 Topics: Algorithms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Databases, Factual; Enzyme Activation; Enzyme Inhibitors; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Protein Binding; Quantitative Structure-Activity Relationship	2005
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones	2009
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer. Journal of medicinal chemistry, 2021, 08-12, Volume: 64, Issue:15 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoricoxib; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Structure-Activity Relationship	2021
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proceedings of the National Academy of Sciences of the United States of America, 2001, Dec-04, Volume: 98, Issue:25 Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones	2001
Pharmacological characterisation of a rat model of incisional pain. British journal of pharmacology, 2004, Volume: 141, Issue:1 Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Evaluation, Preclinical; Etoricoxib; Foot; Gabapentin; gamma-Aminobutyric Acid; Hindlimb; Hyperalgesia; Indomethacin; Male; Morphine; Muscle, Skeletal; Naproxen; Nociceptors; Pain Threshold; Pain, Postoperative; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Sulfones; Time Factors; Weight-Bearing	2004
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomedical chromatography : BMC, 2006, Volume: 20, Issue:1 Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Etoricoxib; Humans; Isoxazoles; Ketoprofen; Male; Pyrazoles; Pyridines; Rats; Rats, Wistar; Reproducibility of Results; Salicylic Acid; Spectrophotometry, Ultraviolet; Sulfonamides; Sulfones	2006
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke, 2006, Volume: 37, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Etoricoxib; Female; Humans; Lactones; Logistic Models; Male; Medical Records Systems, Computerized; Middle Aged; Odds Ratio; Pyrazoles; Pyridines; Sulfonamides; Sulfones; United Kingdom	2006
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug safety, 2006, Volume: 29, Issue:8 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; England; Etoricoxib; Female; Humans; Incidence; Lactones; Male; Middle Aged; Pyrazoles; Pyridines; Research Design; Retrospective Studies; Skin; Stevens-Johnson Syndrome; Sulfonamides; Sulfones; Surveys and Questionnaires	2006
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Approval; Drug Evaluation, Preclinical; Etoricoxib; European Union; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboembolism	2006
Coxibs: can this class of drugs survive? Vascular health and risk management, 2005, Volume: 1, Issue:1 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2005
COX-2 inhibitor. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:10 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Osteoarthritis; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones	2007
Use and misuse of the p-value. Bulletin of the NYU hospital for joint diseases, 2008, Volume: 66, Issue:2 Topics: Biomedical Research; Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Sample Size; Statistics as Topic; Sulfonamides; Sulfones	2008
Superiority, equivalence, and non-inferiority trials. Bulletin of the NYU hospital for joint diseases, 2008, Volume: 66, Issue:2 Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Statistics as Topic; Sulfonamides; Sulfones; Thrombolytic Therapy; Treatment Outcome	2008
Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:1 Topics: Adolescent; Adult; Betahistine; Celecoxib; Child; Databases, Factual; Drug Labeling; Etoricoxib; Family Practice; Female; Humans; Male; Medication Errors; Netherlands; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Young Adult	2009
Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2009, Apr-05, Volume: 49, Issue:3 Topics: Adult; Aged; Arthritis; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Mass Spectrometry; Middle Aged; Pyrazoles; Pyridines; Reference Standards; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Sulfones; Synovial Fluid; Young Adult	2009
Influence of COX-2-induced PGE2 on the initiation and progression of tail regeneration in Northern House Gecko, Hemidactylus flaviviridis. Folia biologica, 2008, Volume: 54, Issue:6 Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Female; Lizards; Male; Pyrazoles; Pyridines; Regeneration; Sulfonamides; Sulfones; Tail	2008
Study on mechanism for amorphous drug stabilization using gelucire 50/13. Chemical & pharmaceutical bulletin, 2009, Volume: 57, Issue:9 Topics: Calorimetry, Differential Scanning; Celecoxib; Cyclooxygenase Inhibitors; Drug Compounding; Drug Stability; Etoricoxib; Excipients; Fats; Hydrogen Bonding; Oils; Povidone; Pyrazoles; Pyridines; Spectrophotometry, Infrared; Sulfonamides; Sulfones; X-Ray Diffraction	2009
COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Drug Hypersensitivity; Etoricoxib; Female; Humans; Male; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2009
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. PharmacoEconomics, 2010, Volume: 28, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen; Pyrazoles; Pyridines; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Treatment Outcome; United Kingdom	2010
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. Clinical therapeutics, 2010, Volume: 32, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Peptic Ulcer; Prospective Studies; Pyrazoles; Pyridines; Risk Factors; Sulfonamides; Sulfones; Taiwan	2010
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5 Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis	2010
Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice. Neuro endocrinology letters, 2011, Volume: 32, Issue:2 Topics: Acetaminophen; Acetic Acid; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Celecoxib; Codeine; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Etoricoxib; Ibuprofen; Male; Mice; Mice, Inbred Strains; Models, Animal; Pain; Pyrazoles; Pyridines; Regression Analysis; Sulfonamides; Sulfones	2011
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells. Pharmacological research, 2012, Volume: 65, Issue:1 Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones	2012
Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib. Contact dermatitis, 2012, Volume: 66, Issue:2 Topics: Aged; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Isoxazoles; Leg Dermatoses; Low Back Pain; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2012
Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:3 Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2014
Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis care & research, 2015, Volume: 67, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Registries; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Sweden; Young Adult	2015
Toward a Better Understanding of the Physical Stability of Amorphous Anti-Inflammatory Agents: The Roles of Molecular Mobility and Molecular Interaction Patterns. Molecular pharmaceutics, 2015, Oct-05, Volume: 12, Issue:10 Topics: Anti-Inflammatory Agents; Celecoxib; Crystallization; Dielectric Spectroscopy; Drug Stability; Etoricoxib; Lactones; Pyridines; Sulfones	2015
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria. Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32 Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones	2016
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2016, Volume: 35, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Neovascularization, Pathologic; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones	2016
Trends in celecoxib and etoricoxib prescribing following removal of prior authorization requirement in Spain. Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:2 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Utilization; Etoricoxib; Humans; Pyridines; Spain; Sulfones	2017
Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer. Cancer investigation, 2017, Aug-09, Volume: 35, Issue:7 Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Transformation, Neoplastic; Colon; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Glycogen Synthase Kinase 3 beta; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Rats, Sprague-Dawley; Sulfones; Time Factors; Wnt Signaling Pathway	2017
[Cognitive-cytokine effect of nonsteroidal antiinflammatory drugs in the therapy of elderly patients with osteoarthritis]. Advances in gerontology = Uspekhi gerontologii, 2017, Volume: 30, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Cognition Disorders; Cytokines; Etoricoxib; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Meloxicam; Osteoarthritis; Prospective Studies; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Transforming Growth Factor beta1	2017
Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib. Contact dermatitis, 2019, Volume: 81, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Blister; Celecoxib; Drug Eruptions; Etoricoxib; Female; Humans; Middle Aged; Patch Tests	2019
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. BMC cancer, 2021, May-03, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway	2021
Potent Phenylpyridine and Oxodihydrofuran Inhibitors of Cyclooxygenase-2: Optimization toward a Long Residence Time with Balanced Internal Energetics. Biochemistry, 2021, 08-10, Volume: 60, Issue:31 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Discovery; Enzyme Assays; Etoricoxib; Fluorescence; Furans; Humans; Hydrogen; Kinetics; Mass Spectrometry; Models, Theoretical; Oxygen; Pyrazoles; Pyridines; Thermodynamics; Time Factors	2021
Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders. Headache, 2022, Volume: 62, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Headache; Headache Disorders; Humans; Indomethacin	2022
Association between tramadol use and risk of pneumonia in the middle-aged and elderly populations: a propensity-score matched cohort study. European journal of pain (London, England), 2022, Volume: 26, Issue:6 Topics: Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Codeine; Cohort Studies; Diclofenac; Etoricoxib; Humans; Middle Aged; Naproxen; Pneumonia; Tramadol	2022
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials. Drug safety, 2022, Volume: 45, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etodolac; Etoricoxib; Female; Heart Disease Risk Factors; Humans; Meloxicam; Risk Factors	2022
[Selective cyclooxygenase-2 inhibitor hypersensitivity]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 2023, Jan-04, Volume: 69, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Hypersensitivity; Etoricoxib; Humans; Hypersensitivity; Male; Sulfonamides; Sulfones	2023
Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics. International journal of pharmaceutics, 2023, Oct-15, Volume: 645 Topics: Bariatric Surgery; Bariatrics; Celecoxib; Cyclooxygenase 2 Inhibitors; Etodolac; Etoricoxib; Humans; Solubility	2023
Remission of Dowager's hump by manipulative correction of spinal alignment: a case report. Journal of medicine and life, 2023, Volume: 16, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Female; Headache; Humans; Kyphosis; Lordosis; Manipulation, Chiropractic; Neck Pain; Radiography; Remission Induction	2023

chemdatabank.com